PriceSpective’s Asset Valuation Practice

PriceSpective's Asset Valuation (AV) Practice is uniquely positioned to deliver expert guidance in licensing valuations, global pricing and market access due diligence and deal negotiations for companies ranging from large pharma to the smallest of biotech.

We deliver strategic insights to our clients by leveraging PriceSpective's in-house deal experience combined with our deep pricing, reimbursement and therapeutic area expertise to determine future price expectations, likely levels of reimbursement and resulting forecast effects.

PriceSpective’s Asset Valuation Practice truly provides our clients with a strategic advantage in licensing and M&A transactions.

Our Capabilities
Corporate Business Development Strategy

• Develop BD strategy by identifying areas of opportunity based on unmet medical need and commercial potential
• Assist clients in formal strategic and tactical planning for partnership, licensing, and M&A activities
• Identify new and existing products, technologies, and businesses to partner, in-license, out-license, acquire, or divest.

Our Approach to Asset Valuation

The Asset Valuation practice leverages PriceSpective's extensive stakeholder network and deep pricing and market access expertise to rapidly deliver real-world tested value assessments to our clients.